Keybank National Association OH Buys 134,862 Shares of Illumina, Inc. (NASDAQ:ILMN)

Keybank National Association OH boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 52.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 392,014 shares of the life sciences company’s stock after acquiring an additional 134,862 shares during the quarter. Keybank National Association OH’s holdings in Illumina were worth $52,385,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Bleakley Financial Group LLC purchased a new stake in shares of Illumina in the fourth quarter worth approximately $751,000. Zacks Investment Management purchased a new stake in shares of Illumina in the third quarter worth $2,924,000. Van ECK Associates Corp lifted its stake in Illumina by 17.5% during the fourth quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock worth $20,347,000 after purchasing an additional 22,718 shares during the last quarter. Strategic Financial Concepts LLC purchased a new stake in Illumina during the 4th quarter valued at about $1,464,000. Finally, Allworth Financial LP boosted its holdings in shares of Illumina by 720.7% during the fourth quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock worth $1,001,000 after purchasing an additional 6,263 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $84.20 on Tuesday. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12-month low of $83.79 and a 12-month high of $156.66. The company’s fifty day moving average is $122.36 and its two-hundred day moving average is $132.81. The company has a market cap of $13.34 billion, a P/E ratio of -10.96, a price-to-earnings-growth ratio of 1.60 and a beta of 1.10.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on ILMN shares. TD Cowen downgraded shares of Illumina from a “buy” rating to a “hold” rating and cut their target price for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Barclays downgraded shares of Illumina from an “equal weight” rating to an “underweight” rating and lowered their target price for the stock from $130.00 to $100.00 in a report on Monday, February 10th. Royal Bank of Canada decreased their price objective on Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. UBS Group raised their price objective on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, HSBC downgraded Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a report on Friday. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $155.45.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.